SCHEMBL4045955

SCHEMBL4045955

CC(=O)c1cn(S(=O)(=O)c2ccccc2)c2c(Br)cccc12

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.65
SMN1; SMN2 Q16637 1/20 0.65
AKR1C3 P42330 1/20 0.49
AKR1C1 Q04828 1/20 0.49
PLK1 P53350 1/20 0.48
MEN1 O00255 1/20 0.48
KMT2A Q03164 1/20 0.48
TNF P01375 3/20 0.42
PKM P14618 1/20 0.42
HTR6 P50406 7/20 0.41
ALOX5 P09917 1/20 0.40
PTGS2 P35354 1/20 0.40
TNFSF11 O14788 1/20 0.40
BRD4 O60885 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
HDAC1 Q13547 2/20 0.38
HDAC6 Q9UBN7 2/20 0.38
HDAC3 O15379 1/20 0.38
HDAC4 P56524 1/20 0.38
HDAC7 Q8WUI4 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30393652 0.79 LMNA (1.00) LMNASMN1; SMN2AKR1C3AKR1C1PLK1
SCHEMBL949716 0.79 LMNA (1.00) LMNASMN1; SMN2AKR1C3AKR1C1PLK1
SCHEMBL12748677 0.76 AKR1C3 (0.54) LMNASMN1; SMN2AKR1C3AKR1C1PLK1
SCHEMBL4047014 0.76 KDM4E (0.52) LMNASMN1; SMN2AKR1C3AKR1C1PLK1
SCHEMBL19194701 0.75 LMNA (0.71) LMNASMN1; SMN2AKR1C3AKR1C1PLK1
SCHEMBL946621 0.75 LMNA (0.71) LMNASMN1; SMN2AKR1C3AKR1C1PLK1
SCHEMBL1466938 0.74 AKR1C3 (0.56) LMNASMN1; SMN2AKR1C3AKR1C1PLK1
SCHEMBL12748681 0.74 AKR1C3 (0.52) LMNASMN1; SMN2AKR1C3AKR1C1PLK1
SCHEMBL1468084 0.73 AKR1C3 (0.54) LMNASMN1; SMN2AKR1C3AKR1C1PLK1
SCHEMBL1465894 0.73 AKR1C3 (0.54) LMNASMN1; SMN2AKR1C3AKR1C1PLK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101166746-B Process for preparing substituted benzothiazinoindoles SUVEN LIFE SCIENCES LTD 2011-09-28 CN disclosed
EP-1856132-B1 PROCESS FOR PREPARING SUBSTITUTED BENZOTHIAZINOINDOLES SUVEN LIFE SCIENCES LTD (IN) 2009-04-01 EP disclosed
US-20080119646-A1 Process for Preparing Substituted Benzothiazinoindoles SUVEN LIFE SCIENCES LIMITED (IN) 2008-05-22 US disclosed
CN-101166746-A Process for preparing substituted benzothiazinoindoles SUVEN LIFE SCIENCES LTD (IN) 2008-04-23 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080119646-A1 Process for Preparing Substituted Benzothiazinoindoles C5, CYP8B1, CBR1 LMNA 1605/4885SMN1; SMN2 4819/4885AKR1C3 19/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.